1	
Please type a plus sign (+) inside this box ->	+

Sheet

Substitute for form 1449A/B/PTO	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary) of

	Complete if Known
Application Number	Unassigned
Filing Date	October 30, 2003
First Named Inventor	Kaye et al.
Group Art Unit	Unassigned
Examiner Name	Unassigned ·
Attorney Docket Number	221749

U.S. PATENT DOCUMENTS						
		U.S. Patent Document				
Examiner Initials	Doc. No.	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Filing Date If Appropriate
77	AA	6,506,559	B1	Fire et al.	Jan. 14, 2003	· · · · · · · · · · · · · · · · · · ·

1

	FOREIGN PATENT DOCUMENTS							
Foreign Patent Document			1	Translation				
Examiner Initials	Doc. No.	Office	Application or Patent Number	Kind Code	Name of Patentee or Applicant	Date of Publication	Yes	No*+
ⅳ	AB	WO	03/004645	A1	The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services	Jan. 16, 2003		
•								

		OTHER - NON PATENT LITERATURE DOCUMENTS		lation		
Examiner Initials	Doc. No. Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number (s), publisher, city and/or country where published.					
Tγ	AC.	TONON et al., "t(11;19)(q21;p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway," <i>Nature Genetics</i> , 33, 208-213 (February 2003)				
	AD.	IOURGENKO et al., "Identification of a family of cAMP response element-binding protein Coactivators by genome-scale functional analysis in mammalian cells," PNAS Early Edition, 1-6 (2003)				
	AE	CONKRIGHT et al., "TORCs: Transducers of Regulated CREB Activity," <i>Molecular Cell</i> , 12, 413-423 (August 2003)				
	AF	WILDA et al., "Killing of leukemic cells with a BCR/ABL fusion gene by RNA interference (RNAi)," Oncogene, 21, 5716-5724 (2002)				
	AG.	SUI et al., "A DNA vector-based RNAi technology to suppress gene expression in mammalian cells," PNAS, 99 (8), 5515-5520 (April 2002)				
	АН	SHI, "Mammalian RNAi for the masses," TRENDS in Genetics, 19 (1), 9-12 (January 2003)				
	AI.	AOKI et al., "RNA INTERFERENCE MAY BE MORE POTENT THAN ANTISENSE RNA IN HUMAN CANCER CELL LINES," Clinical and Experimental Pharmacology and Physiology, 30, 96-102 (2003)				
	AJ.	CIOCA et al., "RNA interference is a functional pathway with therapeutic potential in human myeloid leukemia cell lines," Cancer Gene Therapy, 10, 125-133 (2003)				
	AK.	BRUMMELKAMP et al., "Stable suppression of Tumorigenicity by virus-mediated RNA interference," Cancer Cell, 2, 243-247 (September 2002)				
	AL,	LIN et al., "D-RNAi (Messenger RNA-antisense DNA Interference) as a Novel Defense System Against Cancer and Viral Infections," Current Cancer Drug Targets, 1, 241-247 (2001)				
V	AM.	BORKHARDT, "Blocking oncogenes in malignant cells by RNA interference-New hope for a highly specific cancer treatment?," Cancer Cell, 167-168 (September 2002)				

Examiner Signature Date Considered milano To

A concise statement of relevance is being somitted in lieu of a translation. 37 CFR 1.98(a)(3).
An English-language equivalent/patent, or an English-language abstract, or an English-language version of the search report or action by a foreign patent office in a counterpart foreign application indicating the degree of relevance found by the foreign office is being submitted in lieu of a concise explanation of relevance under 37 CFR 1.98(a)(3).